» Articles » PMID: 10694729

Sample Size Considerations for the Evaluation of Prognostic Factors in Survival Analysis

Overview
Journal Stat Med
Publisher Wiley
Specialty Public Health
Date 2000 Mar 1
PMID 10694729
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

When the role of a new prognostic factor is investigated, careful planning of an appropriate study is required. This includes an assessment of the power of the study in terms of sample sizes. An adequate analysis of the independent prognostic effect of a new factor has to be adjusted for the existing standard factors. With survival time as endpoint this will usually be done with the Cox proportional hazards model. Sample size and power formulae in survival analysis have been developed by Schoenfeld for randomized treatment comparisons. In the analysis of prognostic factors the covariates included are expected to be correlated with the factor of primary interest. In this situation, the existing sample size and power formulae are not valid and may not be applied. In this paper, Schoenfeld's formula is first extended to the situation where a correlated factor is included in the analysis. The validity of the resulting approximate asymptotic formula is investigated for its asymptotic behaviour by numerical integration and for its finite behaviour by simulation. Second, an approximate formula for sample size and power is provided to detect an interaction between the interesting and a second correlated factor. This extends the formula for independent effects. Finally, the approach is illustrated by an example on the prognostic impact of DNA ploidy and other factors in advanced ovarian cancer.

Citing Articles

Predictors of outcome in sciatica patients following an epidural steroid injection: the POiSE prospective observational cohort study protocol.

Stynes S, Snell K, Riley R, Konstantinou K, Cherrington A, Daud N BMJ Open. 2023; 13(11):e077776.

PMID: 37984960 PMC: 10660415. DOI: 10.1136/bmjopen-2023-077776.


Injury Patterns and Incidence in an Elite Youth Football Academy-A Prospective Cohort Study of 138 Male Athletes.

Weishorn J, Jaber A, Zietzschmann S, Spielmann J, Renkawitz T, Bangert Y J Clin Med. 2023; 12(19).

PMID: 37834782 PMC: 10573676. DOI: 10.3390/jcm12196138.


Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials.

Vale C, Fisher D, Godolphin P, Rydzewska L, Boher J, Burdett S Lancet Oncol. 2023; 24(7):783-797.

PMID: 37414011 PMC: 7616350. DOI: 10.1016/S1470-2045(23)00230-9.


Joint inference of physiological network and survival analysis identifies factors associated with aging rate.

Sethi A, Melamud E Cell Rep Methods. 2023; 2(12):100356.

PMID: 36590696 PMC: 9795372. DOI: 10.1016/j.crmeth.2022.100356.


Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III-trial AGITG-MAX.

van Dijk E, van Werkhoven E, Asher R, Mooi J, Espinoza D, van Essen H Int J Cancer. 2022; 151(7):1166-1174.

PMID: 35489024 PMC: 9545440. DOI: 10.1002/ijc.34061.